Molecular Imaging
16
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (16)
Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Molecular Breast Imaging (MBI)-Guided Biopsy
68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma
Clinical Validation of Multimodal Digestive Endoscopy
In Vivo EGFR Molecular Classification and Treatment Response
Rosuvastatin Effect on Atherosclerotic Plaque Metabolism
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
Molecular Evaluation in Metastatic Breast Cancer
In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
EGFR Molecular Classification In Vivo
Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue
In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule